Stress, Cortisol, and Cancer Treatment: A New Drug Changes the Game
A new development in oncology is highlighting something most cancer patients don’t realize: stress and cortisol directly impact cancer treatment outcomes. This matters across breast cancer, colorectal cancer, colon cancer, ovarian cancer, lung cancer, pancreatic cancer, melanoma, and more. Essentially all cancers except for leukemias and lymphomas.
A newly approved drug, relacorilant (brand name Lifyorli), developed by Corcept Therapeutics, introduces a new approach to cancer therapy: blocking cortisol instead of attacking the tumor directly.
How Cortisol Affects Tumor Growth and Cancer Therapy
Cortisol, the body’s primary stress hormone, does more than affect mood. In cancer biology, it promotes tumor survival, increases metastasis risk, and suppresses immune function.
This has direct implications for chemotherapy and immunotherapy for cancer. Even if treatment is working, elevated cortisol can:
- Protect tumor cells from chemotherapy
- Reduce immune response during immunotherapy
- Increase resistance to cancer treatment in general
- Increase the growth and invasiveness of the cancer itself
This means stress and cortisol are not just lifestyle concerns—they are biological factors in cancer progression.
Clinical Trial Results in Ovarian Cancer Treatment
The approval of relacorilant came from a well-designed clinical trial in treatment-resistant ovarian cancer.
Patients receiving relacorilant with chemotherapy (paclitaxel) showed:
- 35% improvement in overall survival
- 30% improvement in progression-free survival
Notably, this happened even though the chemotherapy dose was lower than the control group.
This shows that blocking cortisol both makes chemotherapy more effective and reduces chemotherapy dose and side effects.
Why This Matters Beyond Ovarian Cancer
Although currently approved for only for resistant ovarian cancer, this mechanism likely applies broadly across oncology.
Many cancers—including breast cancer, prostate cancer, kidney cancer, colorectal cancer, and lung cancer—are influenced by stress hormones. Blocking cortisol signaling could enhance outcomes across cancer types, and since relacorilant is blood-brain-barrier permeant that includes GBM.
However, there are exceptions. Blood cancers such as lymphoma and leukemia respond differently, as steroids are part of their treatment.
Steroids, Stress Management, and Cancer Outcomes
This also raises an important question about common oncology practices.
Steroids like prednisolone are often used alongside chemotherapy and immunotherapy. While helpful for managing side effects, they also suppress immune function and reduce treatment effectiveness.
The success of relacorilant highlights the importance of minimizing unnecessary steroid exposure when possible. Adding dexamethasone or prednisone is the opposite of what relacorilant does, and would cause significant worsening.
At the same time, stress management becomes more than supportive care. Reducing cortisol—through behavioral strategies or medication—clearly improves cancer treatment outcomes in a meaningful way.
A Shift in How We Think About Cancer Treatment
This is not a replacement for chemotherapy, immunotherapy, or targeted cancer therapy. It is an adjuvant approach—one that improves how existing primary treatments work.
For cancer patients, this reinforces a critical point: biology matters. Stress, hormones, and immune function are not separate from treatment—they are part of it.
Understanding and managing these factors may be as important as choosing the right drug.
Accurate science saves lives — and it starts with rejecting simple myths in favor of real understanding. Stay curious.
Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace guidance from your healthcare provider. Cancer and treatment decisions are highly individual—always consult your physician or qualified healthcare professional regarding your specific situation.
A full disclaimer is available Terms and Conditions.